IPSEY Ipsen S.A.
Latest News

$33.901.67 (+5.20%)3:59 PM 05/14/24

Pink Limited Info | $USD | Market Close

Summary
Ratings
Financials
Earnings
Dividends
Valuation
Growth
Profitability
Momentum
Peers
Options
Charting

All
Analysis
Comments
News
Transcripts
SEC Filings
Press Releases
Related Analysis

IPSEY News

Show Full Stories

This feature available only for pro users

Type:

Date Range:

Ipsen S.A. reports Q1 results; reaffirms full-year guidance

SA NewsWed, Apr. 24

Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases

SA NewsMon, Apr. 22

Ipsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADC

SA NewsTue, Apr. 02

Ipsen gets FDA approval for pancreatic cancer drug regimen

SA NewsTue, Feb. 131 Comment

Merrimack spikes as Ipsen wins FDA label expansion for cancer therapy

SA NewsTue, Feb. 132 Comments

Ipsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlook

SA NewsThu, Feb. 08

Public Citizen petitions FDA for stricter warnings against Botox, similar drugs

SA NewsTue, Dec. 12, 20232 Comments

FDA grants priority review of Genfit-Ipsen liver disease drug

SA NewsThu, Dec. 07, 20231 Comment

Genfit stock rallies 20% after hours on data for liver disease drug

SA NewsMon, Nov. 13, 20231 Comment

Ipsen reports Q3 results; reaffirms FY 23 guidance

SA NewsThu, Oct. 26, 2023

CymaBay says liver disease candidate outperformed in Phase 3 trial

SA NewsThu, Sep. 07, 20231 Comment

Exelixis lead product hits main goal in Phase 3 prostate cancer trial

SA NewsMon, Aug. 21, 20231 Comment

Ipsen wins FDA approval of rare bone disease drug palovarotene

SA NewsWed, Aug. 16, 2023

Ipsen S.A. GAAP EPS of €2.35, revenue of €1.54B

SA NewsThu, Jul. 27, 2023

Ipsen bone disorder therapy rejected in EU

SA NewsWed, Jul. 19, 2023

Genfit gains as Phase 3 trial for liver disease candidate succeeds (update)

SA NewsFri, Jun. 30, 20232 Comments

Ipsen wins FDA AdCom nod for bone disease therapy

SA NewsThu, Jun. 29, 2023

Mirum falls as FDA expands label for Ipsen’s liver disease therapy

SA NewsWed, Jun. 14, 2023

Ipsen appoints new chief medical officer

SA NewsMon, Apr. 24, 2023

New FDA action date in August for Ipsen bone disease drug palovarotene

SA NewsThu, Mar. 16, 20231 Comment

Bristol Myers Opdivo, Exelixis/Ipsen's Cabometyx combo shows survival benefit in kidney cancer in 3 year data

SA NewsTue, Feb. 14, 20233 Comments

Ipsen S.A. Non-GAAP EPS of €10.51, revenue of €3.02B; initiates FY23 guidance

SA NewsThu, Feb. 09, 2023

Ipsen faces another setback for bone disorder drug with EMA panel's rejection

SA NewsFri, Jan. 27, 2023

Ipsen presents full data showing 'survival benefit' in pancreatic cancer in phase 3 trial

SA NewsFri, Jan. 20, 20231 Comment

Albireo stock jumps 85% as Ipsen set to acquire it for ~$952M

SA NewsMon, Jan. 09, 20232 Comments

Ipsen says FDA rejected treatment for rare bone disorder

SA NewsTue, Dec. 27, 2022

Exicure says development collaborations with AbbVie, Ipsen terminated

SA NewsWed, Dec. 14, 20221 Comment

Exelixis says lung cancer therapy failed in Phase 3 trial

SA NewsFri, Dec. 09, 20222 Comments

Merrimack jumps 183% as partner Ipsen says pancreatic cancer trial met main goal

SA NewsWed, Nov. 09, 20226 Comments

Ipsen Onivyde combo meets trial's survival goal in untreated pancreatic cancer patients

SA NewsWed, Nov. 09, 20223 Comments

Ipsen S.A. reports Q3 results; reaffirms FY22 guidance

SA NewsThu, Oct. 27, 2022

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

SA NewsTue, Aug. 09, 2022

Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance, required shares

SA NewsFri, Aug. 05, 20225 Comments

Ipsen Onivyde fails to improve overall survival of lung cancer patients in phase 3 trial

SA NewsWed, Aug. 03, 2022

Ipsen to pay $45M upfront to advance Marengo's 2 immuno-oncology candidates

SA NewsMon, Aug. 01, 2022

Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

SA NewsMon, Aug. 01, 2022

Ipsen S.A. Non-GAAP EPS of €4.74, revenue of €1.43B

SA NewsThu, Jul. 28, 2022

Ipsen's rare bone/tissue disorder drug gets FDA priority review

SA NewsWed, Jun. 29, 2022

Epizyme stock soars 60% as Ipsen set to acquire the cancer drugmaker

SA NewsMon, Jun. 27, 202210 Comments

Ipsen gets positive opinion in Europe for bladder loss control drug Dysport

SA NewsThu, Jun. 09, 20221 Comment

12 3 4 5 Next

IPSEY Ipsen S.A.
Latest News

IPSEY News

People Also Follow

Similar to IPSEY

ETFs Holding IPSEY

IPSEY Ipsen S.A.Latest News

IPSEY News

People Also Follow

Similar to IPSEY

ETFs Holding IPSEY

IPSEY Ipsen S.A.
Latest News